Anti-infective Agents Market Size, Share, Growth Analysis, By Type (Revenue, USD Billion; 2013 - 2026)(Antibacterial, Antiviral), By Antibacterial Drug Class (Revenue, USD Billion, 2013 - 2026)(Cephalosporins, Penicillin), By Antibacterial Route of Administration (Revenue, USD Billion, 2013 - 2026)(Topical, Oral), By Antifungal Drug Class (Revenue, USD Billion, 2013 - 2026)(Azoles, Echinocandins), By Antifungal Route of Administration (Revenue, USD Billion, 2013 - 2026)(Topical, Oral), By Antiviral Route of Administration (Revenue, USD Billion, 2013 - 2026)(Topical, Oral), By Route of Administration (Revenue, USD Billion, 2013 - 2026)(Topical, Oral), By Distribution Channel (Revenue, USD Billion, 2013 - 2026)(Hospital Pharmacies, Retail Pharmacies), By Regional (Revenue, USD Billion; 2013 - 2026)(North America, The U.S.) - Industry Forecast 2024-2031

Segmentation Analysis:

The Anti-infective Agents Market is segmented by Type (Revenue, USD Billion; 2013 - 2026), Antibacterial Drug Class (Revenue, USD Billion, 2013 - 2026), Antibacterial Route of Administration (Revenue, USD Billion, 2013 - 2026), Antifungal Drug Class (Revenue, USD Billion, 2013 - 2026), Antifungal Route of Administration (Revenue, USD Billion, 2013 - 2026), Antiviral Route of Administration (Revenue, USD Billion, 2013 - 2026), Route of Administration (Revenue, USD Billion, 2013 - 2026), Distribution Channel (Revenue, USD Billion, 2013 - 2026), Regional (Revenue, USD Billion; 2013 - 2026). We are analyzing the market of these segments to identify which segment is the largest now and in the future, which segment has the highest growth rate, and the segment which offers the opportunity in the future.

• Based on Type (Revenue, USD Billion; 2013 - 2026) the market is segmented as, Antibacterial, Antiviral, Antifungal
• Based on Antibacterial Drug Class (Revenue, USD Billion, 2013 - 2026) the market is segmented as, Cephalosporins, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Others
• Based on Antibacterial Route of Administration (Revenue, USD Billion, 2013 - 2026) the market is segmented as, Topical, Oral, IV, Others
• Based on Antifungal Drug Class (Revenue, USD Billion, 2013 - 2026) the market is segmented as, Azoles, Echinocandins, Polyenes, Others
• Based on Antifungal Route of Administration (Revenue, USD Billion, 2013 - 2026) the market is segmented as, Topical, Oral, IV, Others
• Based on Antiviral Route of Administration (Revenue, USD Billion, 2013 - 2026) the market is segmented as, Topical, Oral, IV, Others
• Based on Route of Administration (Revenue, USD Billion, 2013 - 2026) the market is segmented as, Topical, Oral, IV, Others
• Based on Distribution Channel (Revenue, USD Billion, 2013 - 2026) the market is segmented as, Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, e-Commerce, Others
• Based on Regional (Revenue, USD Billion; 2013 - 2026) the market is segmented as, North America, The U.S., Canada, Europe, Germany, U.K., France, Italy, Spain, Russia, Asia Pacific, Japan, India, China, South Korea, Australia, Singapore, Latin America, Brazil, Mexico, Argentina, Middle East & Africa, UAE, South Africa, Saudi Arabia